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Abstract 
Transferrin, an iron-transporting serum glycoprotein, is efficiently taken up into cells by the process of receptor- 
mediated endocytosis. Transferrin receptors are found on the surface of most proliferating cells, in elevated numbers on 
erythroblasts and on many kinds of tumors. The efficient cellular mechanism for uptake of transferrin has been 
subverted for the delivery of low-molecular-weight drugs, protein toxins, and liposomes by linkage of these agents to 
transferrin or to anti-transferrin receptor antibodies. Linkage may be via chemical conjugation procedures or by the 
generation of chimeric fusion proteins. Transferrin conjugated to DNA-binding compounds (e.g. polycations or 
intercalating agents) has been successfully used for the import of DNA molecules into cells. High-level gene expression 
is obtained only if endosome-disruptive ag nts uch as influenza hemagglutinin peptides or adenovirus particles are 
included which release the DNA complex from intracellular vesicles into the cytoplasm. 
Key words: Adenovirus; DNA transfection; Drug delivery; Endocytosis; Endosome disruption; Gene transfer; Gene 
therapy; Immunotoxin; Polylysine; Transferrin 
1. Introduction 
The high efficacy of the transferrin endocytosis 
process has tempted many investigators to ask 
whether this pathway could be exploited for the 
targeted elivery of drugs or larger molecules into 
cells. The first part of this article reviews the deliv- 
ery of drugs and toxin proteins. A series of suc- 
cessful application in vitro and in vivo have been 
described. The use of toxin proteins appears parti- 
cularly advantageous because the successful deliv- 
ery of one to two toxin molecules to the cytoplasm 
may kill a cell, thereby providing a most sensitive 
test system which is essential for further improve- 
ment of the delivery systems. Recent advances in 
molecular biology have also supplied sensitive de- 
tection methods to assess gene transfer techniques. 
The major part of this review discusses the use of 
the transferrin uptake pathway for the delivery of 
genes into cells. This concept may broaden the 
range of applications, as genes may be designed 
to have either a cytotoxic or a biologically cura- 
tive effect on cells, and the gene products may be 
produced in numerous copies over an extended 
period. The first section describing the natural 
role of transferrin has been kept short; extensive 
reviews on the structure and physiology of trans- 
ferrin and the transferrin receptor can be found 
elsewhere [1-3]. 
2. Physiology of transferrin and transferrin receptor 
2.1. Transferrin (Tf) and transferrin receptor 
( TfR ) 
Transferrin (Tf) is an abundant serum compo- 
nent with the capacity to bind and transport iron. 
The main function of this 80-kDa glycoprotein 
[4,5] consists of providing cells with iron which 
they need in the process of DNA synthesis for the 
activity of ribonucleotide reductase, and for spe- 
cialized functions (synthesis of hemoglobin in reti- 
culocytes; iron transport o the fetus in syncytial 
trophoblasts). Iron is supplied to cells by attach- 
ment of iron-loaded Tf  to its specific cell surface 
receptor followed by receptor-mediated ndocyto- 
sis, a process that efficiently internalizes receptor- 
bound transferrin into cells. The transferrin recep- 
tor, a dimeric transmembrane glycoprotein of 180 
kDa [6,7], is present on the surface of most prolif- 
erating higher eukaryotic ells [8,9]. Erythroblasts 
express particularly elevated numbers of up to 
800 000 TfR per cell. Proliferating TfR-expres- 
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sing tissues include bone marrow, intestinal 
epithelium, and epidermis, but expression is also 
found in a few non-proliferating tissues such as 
hepatocytes, tissue macrophages, pituitary cells, 
pancreas islet cells, or the endothelium of brain 
capillaries. Tumor cells frequently carry elevated 
numbers of TfR compared with the correspond- 
ing normal cells. In tumor-bearing patients re- 
duced serum levels of Tf are often observed. 
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2 x 104 Tf molecules internalized per minute per 
cell [13]. A second, minor pathway with a longer 
transit time has been identified as routing to the 
trans-Golgi and then back to the plasma mem- 
brane [14a]. It also should be kept in mind that 
modification of Tf, crosslinking the receptor (e.g. 
by the use of antibodies or multivalent ligands 
[14b]) and/or lysosomotropic agents may strongly 
influence the intracellular fate of Tf. 
2.2. Receptor-mediated ndocytosis and the 
intracellular cycle 
Receptor-mediated ndocytosis is a natural 
process which cells utilize for the uptake of pro- 
tein or peptides uch as low-density lipoprotein, 
asialoglycoproteins, epidermal growth factor, 
transferrin, insulin, and small vitamins uch as fo- 
lic acid. Many viruses also gain entry to cells via 
receptor-mediated ndocytosis. The first steps in 
this process include binding of the ligand to speci- 
fic cell-surface receptors, receptor clustering and 
internalization through coated vesicles into endo- 
somal acidic compartments. The subsequent path- 
ways are strongly dependent on the type of recep- 
tor/ligand pair; the low endosomal pH may or 
may not trigger dissociation of receptor and li- 
gand, and sorting processes may lead to degrada- 
tive lysosomal compartments. 
The receptor-mediated ndocytosis process of 
Tf differs from other ligand/receptor pairs in sev- 
eral respects. After internalization, iron-loaded Tf 
releases the iron at the low endosomal pH, while 
apoTf (iron-free Tf) remains bound to the recep- 
tor. The receptor-apoTf complex is sorted into 
exocytic vesicles back to the cell surface, where 
apoTf has ca. 30-fold lower affinity for the TfR 
at the extracellular pH and is released into the 
medium. Whether iron-loading is necessary for 
the uptake of Tf-conjugates, has not been tested. 
(With polyvalent Tf conjugates, uch as described 
in Sect. 4.4, iron-loading is no strict requirement 
[our unpublished observation].) The entire Tf cy- 
cle [10-12] may take only 4-5 min (as shown in 
K562 cells with ca. 150 000 TfR per cell) with a 
mean transit time of about 10 min and avoids ly- 
sosomal compartments. The rapid recycling leads 
to very high turnover numbers on the order of 
3.Targeted elivery of drugs, proteins and toxins via 
the transferrin receptor 
3.1. Tf and TfR conjugates for improved uptake into 
cells 
Many low-molecular-weight, pharmacologi- 
cally active compounds are readily taken up into 
cells by passive diffusion processes through the 
cell membrane, whereas the uptake of charged 
molecules or larger compounds uch as peptides, 
proteins, or nucleic acids is restricted. Moreover, 
for several therapeutic applications the specific 
targeting of a subset of cells is desired. A great 
deal of data accumulated during the last decade 
demonstrate that the TfR-mediated endocytosis 
pathway may be exploited to solve both tasks, 
namely enhanced intracellular uptake as well as 
targeted delivery of biologically active com- 
pounds. Low-molecular-weight drugs, protein tox- 
ins, or larger structures such as liposomes or mini- 
beads have been linked to Tf or to antiTfR anti- 
bodies (see Table 1). The linkages were produced 
by a wide variety of chemical conjugation proce- 
dures or by the generation of chimeric antiTfR 
fusion proteins. 
The targeting of drugs or toxins to tumor cells 
by specific antibodies has long been a topic of 
interest [15]. Using monoclonal antibodies gener- 
ated by immunizations with neoplastic cells, 
Trowbridge and Omary [8] and Sutherland and 
colleagues [9] identified the transferrin receptor as 
a major cell surface protein in proliferating cells. 
Based on this discovery, Trowbridge and Domin- 
go synthesized antiTfR antibody conjugates of the 
plant toxin ricin A or the bacterial diphtheria tox- 
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Table 1 
Targeted elivery of compounds conjugated to transferrin or to anti-TfR antibodies 
Compound Conjugated to Target cells Application Special focus Ref. Year 
Adriamycin Tf  in vitro 16 1984 
Tf leukemia cells patients 17 1990 
Tf in vitro mechanism 18,19 1992 
ctTfR 5E9 in vitro acid-labile link 20 1990 
aTfR 5E9 Daudi in vivo (nude mice) effect of linker 21,22 1990/1 
Daunorubicin Tf SCCL NC1-H69 23 1991 
Methotrexate ctTfR CEM in vivo 24 1985 
ctTfR CEM in vitro monensin 25 1988 
ctTfR in vivo blood brain barrier 26 1991 
Ricin A-chain ctTfR B3/25 CEM, M21 in vitro 
bone marrow in vitro 
hTf  CEM in vitro 
Tf  or ~TfR in vitro 
Whole ricin ~tTfR brain tumor (GBM) 
Ricin A ctTfR 7D3, 454A12 mesothelioma nude mice, i.p. 
Ricin A ct-muTfR R17 217, P88D1 syngeneic tumor 
YE1/9.9 i.p. 
Ricin A Tf or :tTfR CEM in vitro 
Ricin A hTf  glioma, Jurkat 
Ricin A ctTfR 454A12 CEM, MCF-7 
Whole ricin ctTfR CEM intratumor 
Ricin A ctTfR 7D3 glioma cells in vitro 
Ricin A Tf, OKT9, Jurkat, CEM, 9L, in vitro 
OX26ctTfR Hu214 
Ricin A ~tTfR MEM75 HL60, KG1, U937, in vitro 
120-2A3 K562 
Ricin A Tf  or ctTfR R17 217 hybridoma in vitro 
Ricin A :tTfR 7D3 R17 217 mesothelioma colon in vivo 
carcinoma 
nude mice 27 1981 
28 1984 
29 1984 
monensin 30 1984 
31 1987 
monensin 32 1987 
33 1987 
monensin 34 1987 
monensin 35 1988 
lysosomatropic agents 36 1989 
solid tumors 37 1989 
monensin 38 1990 
HSA-monensin conjugates 39 1990 
leukemia 40 1991 
intracell, path. monensin 41 1991 
monensin/lipid emulsion 42 1991 
Diphtheria ~TfR in vitro 
toxin (DT) 
DT A-chain Tf  LMTK- in vitro 
CRM 107 Tf Jurkat, K562, SNB75 in vitro 
DT Tf  LMTK-variant in vitro 
CRM 103, 9 Tf  Jurkat in vitro 
DT-A-chain Tf  L-cell mutant in vitro 
DT388-ctTfR A431, KB, MCF7, 
fusion OVCAR3, HUT102 
Pseudomonas uTfR B3/25, HB21 KB, A431, HUT-102 in vitro 
exotoxin 
:tTfR KB, A431, OVCAR in vitro 
ctTfR HB21 ovarian cancer nude mice 
(Lys)PE40 ~TfR A431 nude mice, i.p. 
PE40-ctTfR A431, KB, MCF7, 
fusion OVCAR3, HUTI02 
27 1981 
43 1985 
cytosol translocation 44 1988 
Tf recycling 45 1988 
acid-labile link 46 1989 
resistance 47 1991 
48 1991 
adenovirus 
verapamil, diltiazem 
s.c. tumor 
49 1983 
50,51,52 1984/5 
53 1986 
54 1989 
48 1991 
Saporin-6 hTf K562 in vitro 
hTf  Jurkat, CEM, 9L, 
Hu214 
~TfR leukemic ells 
HSA-monensin conjugates 
55 1988 
39 1990 
56 19~ 
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Table 1 (Continued) 
Compound Conjugated to Target ce l l s  Application Special focus Ref. Year 
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Gelonin ~TfR Namalwa in vivo 
Tf HL60 resistance 
Pokeweed c~TfR HSB-2, CEM, in vitro chloroquine 
antiviral MOLT-3 
protein eTfR 5E9 HSB-2 in vitro in vivo stability 
c~TfR photoactivation 
Barley toxin c~TfR 
Neocarzino- Tf K562 in vitro 
statin 
Abrin variant hTf glioblastoma, in vitro monensin 
melanoma 
Cholera toxin GM10S-Tf in vitro 
RNaseA ~TfR or Tf K562 in vitro 
~TfR 5E-9, 454A12 K562, U251 in vivo, nude mice 
Angiogenin- K562 in vitro 
c~TfR fusion 
protein 
TNF ~TfR K562 in vitro 
fusion protein 
Minibeads Tf leukemic cells, 
reticulocytes 
Tf L2C leukemia 
Polymer Tf or c~TfR skin fibroblasts 
Liposomes Tf L2C leukemia 
+methotrexate c~TfR T-cell leukemia 
+ ara-cytosine Tf CV- 1 
in vitro 
in vitro 
chloroquine 
57 
58 
59 
60 
61 
62 
63 
64 
65 
1987 
1992 
1984 
1985 
1992 
1991 
1985 
1990 
1992 
66 1992 
67 1991 
68 1992 
69 1992 
70 1991 
internalization 7 l 1983 
internalization 72 1987 
73 1989 
internalization 72 1987 
74,75 1989 
76 1990 
in A subunit  [27]. These conjugates displayed ef- 
fective killing of human tumor cells in vitro at 
concentrations up to 1000-fold lower than using 
the ant ibody combined with the non-coupled tox- 
in fragments alone. Tumor  growth inhibit ion was 
also found in a melanoma in vivo model in nude 
mice; however, in these experiments unmodif ied 
ant ibody also mediated growth inhibit ion to a si- 
milar extent (see also ant i tumor activity of 
ant iTfR antibodies described in Refs. 85 88). 
Moreover, in these early experiments, the path- 
way by which the TfR-bound toxins enter the 
cells was not characterized. 
During studies aimed at the elucidation of the 
cellular uptake of iron, Takahashi and Tavassoli 
demonstrated that the iron uptake pathway can 
be subverted for the delivery of 345-nm mini- 
beads linked to Tf  into cellular vesicles of leuke- 
mia cells or reticulocytes [71]. In the same year 
Pastan and colleagues described the delivery of 
Pseudomonas exotoxin-ant iTfR antibody conju- 
gates into cellular endosomes [49]. Subsequent s u- 
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dies have confirmed that the Tf delivery pathway 
is very flexible in accommodating transport of 
both small drugs [16-26], such as adriamycin, and 
structures [72-76] such as Tf-coated liposomes. 
Investigations with TfR-binding toxin conju- 
gates and other immunotoxins had shown that 
despite fficient and specific receptor-mediated en-
docytosis the cytotoxicities were variable and of- 
ten too low to be of therapeutic interest. Often 
natural toxins consist of two polypeptide chains. 
The A-chain contains the activity that inhibits the 
protein synthesis of the target cell, and the B-chain 
contains functions that trigger uptake into cellular 
vesicles and translocation of the A-chain to the 
cytosol. In the construction of immunotoxins the 
B-chain often has been replaced by a ligand such 
as Tf or ~TfR, resulting in enhanced target cell 
specificity but also loss of the mechanism for 
translocation to the cytosol. As a consequence, 
the limiting step in making immunotoxins avail- 
able for their intracellular action seemed to be the 
transport of the toxin part from the vesicular com- 
partment to its target. 
Several strategies have been reported to en- 
hance the delivery and potency of TfR-targeted 
toxin conjugates. Pastan and colleagues had 
shown evidence that adenovirus, after receptor- 
mediated endocytosis, escapes into the cytoplasm 
by disrupting the endosome, thereby liberating 
other substances contained in the same vesicle 
[77]. Consistent with the idea that this disruption 
process may release immunotoxins from internal 
vesicles, the toxicity of Pseudomonas exotoxin con- 
jugated to antiTfR or EGF was enhanced by the 
presence of adenovirus by up to 300-fold [49] or 
10 000-fold [77]. The enhancing activity appeared 
to reside in the protein coat of the virus. Antibo- 
dies against adenoviral penton base blocked the 
enhancing activity without affecting virus uptake, 
suggesting that the penton base is important in 
endosomolysis [78]. 
A series of basic, proton-binding substances 
that influence intracellular routing of endocytosed 
materials also potentiate the action of immuno- 
toxins, such as the lysosomotropic agents ammo- 
nium chloride [36], amines [79] and chloroquine 
[59,66], in addition to some lipophilic carboxylic 
ionophores (monensin, nigericin), and calcium 
channel blockers (verapamil [50-52], diltiazem 
[52], nifedipine). In particular, monensin has been 
shown to strongly enhance the cytotoxicity of im- 
munotoxins such as TfR-targeted ricin A or meth- 
otrexate as described by Raso and colleagues 
[25,30,32,34,38,42] and other groups [35,39,41,65]. 
The mechanism of action of monensin in this pro- 
cess is not clear. Monensin catalyzes cation ex- 
change across lipid bilayers. It has the capacity to 
transport protons across the endosomal mem- 
branes, thereby altering the pH. However, the po- 
tentiating effect on the action of immunotoxins 
exists at relatively low concentrations of monen- 
sin that do not affect endosomal pH, and it seems 
that mechanisms that alter intracellular t afficking 
are involved [41]. For example, monensin has been 
reported to cause accumulation of transferrin in 
perinuclear vesicular compartments, whereas 
chloroquine does not show this effect [14]. An- 
other frequently made observation is that, depend- 
ing on the toxin conjugate, the different lysosomo- 
tropic agents have differential effects. Ammonium 
chloride was found to enhance toxicity of immu- 
notoxins uch as an antiTfR-linked ricin A conju- 
gate [36] whereas the cytotoxic activity of a Tf- 
conjugated iphtheria toxin protein [43] was abol- 
ished by ammonium chloride. Presumably in the 
latter case the pH-triggered translocation of the 
DT A-chain mediated by the B-chain had been 
blocked. 
Further approaches in immunotoxin delivery 
benefit from the efficient natural process by 
which the B-chain specifically assists transloca- 
tion of the A-chain. For this purpose antibody 
conjugates of toxins have been prepared contain- 
ing a "blocked" B-chain with reduced cell-surface 
binding. Diphtheria toxin mutants and conjugates 
thereof have been described by Youle and co- 
workers [44,80]. CRM 107 has 10 000-fold lower 
toxicity and 8 000-fold lower binding activity rela- 
tive to native DT; conjugation to Tf reconstituted 
full activity. Moreover, the Tf-conjugate, unlike 
native DT, was also highly toxic to murine cells. 
Pastan and co-workers [54] constructed the target- 
cell-specific immunotoxin antiTfR-LysPE40 by 
conjugation of antiTfR antibodies with recombi- 
nant 40-kDa fragments of Pseudomonas exotoxin 
that lack its cell-binding domain. 
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The mode of chemical conjugation in the pre- 
paration of immunotoxins creates additional com- 
plexities in the evaluation of biological effects. 
Different linkages containing reducible disulfide 
bonds, non-reducible linkages such as thioethers 
[36], or acid-sensitive linkages [46,81] have been 
found to possess different biological behaviour. 
Moreover chemical cross-linking procedure rarely 
are site-specific and often produce heterogeneous 
products, also containing multiple cross-links. Re- 
cent developments that present elegant alterna- 
tives to chemical conjugation are applications 
where the conjugate consists exclusively of pro- 
tein or peptide components. The Pastan group 
has generated several recombinant immunotoxins 
containing the truncated toxins PE40 or DT388 
linked to single-chain versions of the variable anti- 
body domain directed at the IL-2 receptor [82,83] 
or the TfR [48]. Comparison of chemical conju- 
gates (antiTfR-LysPE40) with the corresponding 
fusion protein showed a 750-fold higher activity 
of the recombinant fusion protein. Similar find- 
ings have been made by Youle and colleagues 
who described a recombinant cytotoxic antiTfR 
RNase fusion protein [69] which is 1000-fold more 
active than the corresponding chemically linked 
RNase hybrids [67,68]. Instead of using conven- 
tional immunogenic bacterial or plant toxins, the 
investigators converted a human serum RNase, 
angiogenin, into an immunotoxin by generating a 
fusion gene of angiogenin with a humanized 
antiTfR antibody heavy chain; expression in chi- 
meric cells that secrete the light chain of the same 
antibody results in the formation of the antibody- 
angiogenin fusion protein. 
3.2. Targeting to various cell types via the 
transferrin receptor 
The constitutive xpression of TfR is found in 
proliferating tissues uch as the bone marrow, epi- 
dermis and intestinal epithelium, and, to a lesser 
extent, in non-proliferating tissues uch as hepato- 
cytes or macrophages. The TfR levels in prolifer- 
ating malignant cells have often been found to be 
far higher than in the corresponding normal cells. 
The increased receptor levels result from changes 
in both proliferation and differentiation: i.e., TfR 
numbers in transformed cells are far higher than in 
non-proliferating cells and may be more than 
twice as high as in the corresponding normal cells 
even when proliferating at the same rate [84]. As 
internalization rates and intracellular outing of 
TfR are similar to that which occurs in normal 
cells [84], an overall enhanced rate of Tf  endocyto- 
sis is observed. For these reasons the TfR has been 
proposed as a target for cancer therapy [85]. 
Trowbridge and colleagues used monoclonal 
antiTfR antibodies to inhibit cell growth in vitro 
[86-87b] and in vivo [27,88] in some tumor sys- 
tems. Other groups have shown that Tf-gallium 
complexes [89], the active form of the chemother- 
apeutic drug gallium nitrate, or Tf-indium com- 
plexes [90] inhibit growth of leukemic cells. The 
TfR-mediated elivery of toxins (see above, Sect. 
3.1) has proven to be particularly effective in spe- 
cifically killing TfR-expressing tumor cells in vi- 
tro. In order to demonstrate a potential applicabil- 
ity for therapy, TfR-targeted immunotoxins have 
been tested in several animal model systems. A 
human ovarian cancer model, where the malig- 
nant cells grow intraperitoneally as ascites in 
nude mice, has been used by Pastan and collea- 
gues. They demonstrated that antiTfR-PE conju- 
gates injected intraperitoneally are able to kill the 
ovarian cancer cells in the peritoneal cavity and 
prolong the survival of mice to 100 days or longer 
[53]. However, extraperitoneal cancer cells were 
not affected by the immunotoxin. In similar mod- 
els for human mesothelioma or colorectal carcino- 
ma Griffin and Raso [32,42] tested the effect of 
ricin A-antiTfR immunotoxin in intraperitoneal 
tumor xenografts in nude mice. Co-administra- 
tion of monensin/lipid emulsion was essential for 
the antitumor effect. Prolonged survival of mice 
with advanced macroscopic intraperitoneal tu- 
mors and cure in 40% of mice with microscopic 
intraperitoneal tumors was observed. 
Immunotoxins containing anti-murine TfR 
antibodies have been applied in a syngeneic peri- 
toneal lymphoid tumor model [33]. McIntyre and 
co-workers reported activity of an antiTfR-gelo- 
nin conjugate against Burkitt's lymphoma neo- 
grafts in nude mice upon direct intratumoral ad- 
ministration into subcutaneous nodules, or intra- 
venous administration at the time of intraperito- 
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neal tumor inoculation [57]. Established solid 
CEM tumors have been shown to completely re- 
gress upon intratumoral injection of whole ricin- 
antiTfR antibody conjugates [37]. Intraperitoneal 
administration of adriamycin-antiTfR antibody 
conjugates [21,22] significantly inhibited the 
growth of subcutaneous solid B-lymphoma xeno- 
grafts in nude mice. The use of Tf-adriamycin in a 
preliminary clinical study in acute leukemia pa- 
tients has been reported [17]. A promising further 
application in vivo has been reported using the 
immunotoxin antiTfR-LysPE40, where intraperi- 
toneal administration caused regression of subcu- 
taneous A431 tumors [54]. 
Targeting via the TfR may also allow delivery 
of compounds into brain tissues where access is 
restricted by the blood/brain barrier. Jefferies and 
colleagues [91] discovered that after injection into 
the blood, monoclonal antibodies against he TfR 
labeled the endothelium of brain capillaries but 
not of other tissues. Further studies showed bind- 
ing, endocytosis and transcytosis of iodine-labeled 
Tf by brain capillaries [92,93]. Only 20% of Tf was 
found to be recycled whereas approximately 50% 
was transcytosed into the brain parenchyma. The 
tight brain capillary wall is devoid of intercellular 
gaps or channels that exist in other endothelial 
layers, and delivery of hydrophilic ompounds by 
processes uch as passive diffusion is prevented. 
The presence of specific transport systems for 
transferrin, insulin [94], amino acids or glucose in 
the capillary endothelial cell layer therefore seems 
to be important for providing the brain with nu- 
trients. Recently, several groups have started to 
use the special transport activity of brain capil- 
laries for the delivery of drugs, peptides, or anti- 
sense oligonucleotides to the brain [for review, see 
Ref. 95]. In order to exploit the Tf transcytosis 
pathway, Friden and colleagues prepared a conju- 
gate between the antiTfR antibody OX-26 and 
methotrexate [26,96]. The conjugates, when in- 
jected intravenously into rats, were targeted to 
the brain capillaries where after 30 min the drug 
had accumulated to levels ca. 50-fold higher than 
unconjugated drug. After a further 24 hours the 
majority of the drug was found in the brain par- 
enchyma fraction which is consistent with a trans- 
cytosis event. Since major distribution to other 
tissues will also occur, the delivery of relatively 
toxic compounds to the brain using antiTfR anti- 
bodies seems not generally applicable. 
Data like those reviewed in this article give ac- 
cumulating evidence that Tf or antiTfR antibodies 
are attractive candidates for the delivery of drugs 
or toxin proteins that are cytotoxic at very low 
doses; for example, one to two ricin A molecules 
are able to kill a cell. However, it is not yet proven 
whether by the use of Tf  or antiTfR antibodies a
sufficiently high targeting specificity can be ob- 
tained that would be required to avoid systemic 
toxicity (e.g. in the liver and bone marrow). The 
approach also suffers from the fact that many of 
the conjugates are highly immunogenic. Humani- 
zation of toxin conjugates is one approach to 
overcome this drawback [69]. Alternative ways 
may include receptor-mediated delivery of genes 
that express toxins or other therapeutic proteins 
(see below) under the control of tissue- or tumor- 
specific promoter elements, for intracellular gen- 
eration of these protein within the target cells, 
thus avoiding some of the immune system expo- 
sure and systemic toxicity. 
4. Transferrin-receptor-mediated gene transfer 
4.1. Viral and non-viral gene transfer methods 
The delivery of nucleic acids and expression of 
the contained genes in eukaryotic ells is a topic of 
increasing interest in molecular and cellular biol- 
ogy as well as in medicine [97,98]. Recombinant 
viral vectors with high gene transfer efficiency 
such as retroviral [99,100], vaccinia virus 
[101,102], adenovirus [103,104] and adenovirus-as- 
sociated virus [105,106] have been developed in 
which part of the viral genome has been replaced 
by a gene to be introduced into eukaryotic ells. 
These vectors, however, can be limited in their 
cell tropism, in the size of the gene to be intro- 
duced, in the compatibility of the introduced 
DNA with viral replication, and the toxicity to 
the cells (e.g. vaccinia virus). 
During the last 30 years non-viral gene transfer 
methods have been elaborated using nucleic acids 
associated with basic proteins [107,108], cationic 
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polymers uch as DEAE-dextran [109,110], poly- 
ornithine [111], polybrene [112], calcium phos- 
phate precipitates [113-115], liposomes [116-118], 
cationic lipids [119,120], lipopolyamines [121,122], 
or electroporation [123,124] and microinjection 
[125]. General reviews are given by Felgner [126] 
and Cotten and Wagner [181]. These gene transfer 
techniques, although still not reaching the efficien- 
cies of viral vectors, have the advantage of being 
very flexible with regard to the type and size of 
nucleic acid to be transported. Most importantly, 
the provision of synthetic gene-transfer vehicles 
with components that mediate specific binding to 
cellular receptors, endocytosis, and delivery to the 
nucleus of the cell may lead to improved gene 
transfer systems with broad applicability. Recent 
developments ( ee below) have demonstrated that 
receptor-mediated ndocytosis pathways can be 
adopted for the delivery of DNA into eukaryotic 
cells. 
4.2. Receptor-mediated en ocytosis of transferrin 
DNA complexes 
More than 10 years ago the first reports were 
published [127,128] describing the concept of ex- 
ploiting natural endocytosis pathways of protein 
ligands for the delivery of DNA macromolecules. 
At that time it was far from obvious that the cel- 
lular endocytosis process of rather small proteins 
may be subverted for the uptake of large (up to 
several hundred nanometers) DNA particles. Sub- 
sequent studies on the TfR-mediated endocytosis 
pathway showed that coupling of Tf to 350 nm or 
50 nm latex minibeads [71,72] or to liposomes [72] 
does not affect the cellular uptake and biological 
activity of Tf in L1210 leukemia cells, rat reticulo- 
cytes, or leukemic LzC cells. Pastan and co-work- 
ers suggested the delivery of DNA to cells by 
covalent linkages to protein ligands such as ~2- 
macroglobulin [127]. More recently, based on this 
idea, Tf-DNA conjugates were prepared [129] 
which were found to bind TfR on rabbit bone 
marrow cells. Alternative approaches use compo- 
sitions containing DNA associated with the pro- 
tein-ligand in non-covalent mode. Stavridis and 
colleagues presented two ways of generating non- 
covalent linkages. Firstly, they showed evidence 
that Tf-coated liposomes containing labeled DNA 
[130] or DNA with the [3-8-globin gene associated 
with non-histone chromosomal proteins [131] were 
bound and partially internalized by rabbit ery- 
throblasts after intravenous injection into rabbits. 
Similar liposomes coated with other ligands for 
cellular binding have been successfully used for 
gene delivery and expression by other groups 
[132,133]. In a second approach presented by the 
group of Stavridis, the interaction of DNA with 
histones was utilized and complexes of tritium-la- 
beled rabbit liver DNA and transferrin cross- 
linked to calf thymus histones were prepared 
[128]. These complexes were preferentially trans- 
ported onto erythroblasts and reticulocytes in ani- 
mal experiments. However, no data have been 
published demonstrating the uptake and expres- 
sion of a gene using this system. 
In order to generate well-defined DNA-binding 
ligands for receptor-mediated gene transfer, Ariat- 
ti and colleagues [134] suggested using proteins 
(such as transferrin and asialoglycoprotein) modi- 
fied with positively charged N-acylurea groups 
that enable electrostatic binding to DNA [135]. 
N-Acylurea-modified transferrin was shown to be 
internalized by HeLa cells [136]. Although there 
are no published data on gene transfer using N- 
acylurea transferrin as ligand, successful gene 
transfer and expression of a CAT marker plasmid 
was demonstrated using insulin conjugated to N- 
acylurea albumin with the insulin serving as cell 
binding ligand and the N-acylurea binding the 
DNA [137]. A related approach developed by Wu 
and colleagues employs conjugates of asialo-oro- 
somucoid and high-molecular-weight cationic 
poly(t,)lysine. Complexes of these DNA-binding 
conjugates with DNA plasmids encoding CAT 
marker genes or therapeutically relevant genes 
were shown to result in gene expression both in 
vitro in cultured HepG2 hepatoma cells [138,139] 
and in vivo in the liver of rats or rabbits [140-144]. 
Using conjugates of human Tf or the avian 
homologue of Tf, conalbumin, with the polyca- 
tions protamine or polylysine acting as the DNA- 
binding moieties, Birnstiel and colleagues [145] 
found efficient transferrin-dependent receptor- 
mediated delivery and expression of luciferase 
marker genes (see Fig. 1) in avian HD3 and hu- 
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Fig. 1. Gene delivery to cells via the TfR-mediated endocytosis 
pathway. 
man K562 erythroid cell cultures [146,147]. Con- 
jugate synthesis involved the modification of 
transferrin and polycations with bifunctional re- 
agents or, in a more specific manner, a ligation 
through the transferrin carbohydrate moiety 
[148]. Optimized delivery of DNA occurred with 
Tf-polycation to DNA ratios that resulted in elec- 
troneutrality. It was demonstrated that the pre- 
sence of excess free transferrin interferes with 
DNA uptake [146] and that up-regulation of the 
transferrin receptor by agents like desferrioxa- 
mine increases the subsequent gene expression in 
K562 cells [147]. Using fluorescence-labeled DNA 
complexes, endocytosis into internal vesicles of 
more than 95% of the cells was found in the ery- 
throid cells [146] and also a series of other cell 
lines [our unpublished results]. In many cell types 
the gene expression was strongly dependent on the 
presence of the lysosomatropic agent chloroquine 
during the transfection (see section below). 
Initially the polycations were considered to be 
simply DNA-attachment elements. A novel type 
of transferrin conjugate was prepared that con- 
tains the DNA-intercalator ethidium homodimer 
instead of polylysine as the DNA-binding group 
[148]. With these conjugates, however, the efficien- 
cies of receptor-mediated gene delivery were con- 
siderably lower compared to the use of optimized 
Tf-polylysine-DNA complexes. Electron micro- 
scopy studies with the most efficient polylysine 
conjugates have shown that DNA, upon complex 
formation, is condensed to small toroid structures 
with a size of 80-100 nm [149]. The condensation 
of the DNA complexes by polylysine and other 
polycations strongly correlated with high gene 
transfer activity [149]. This led to the conclusion 
that packaging of DNA into particles of dimen- 
sions similar to the size of coated pits is impor- 
tant for efficient receptor-mediated endocytosis of 
the complex. Consistent with this hypothesis, the 
DNA delivery with Tfmthidium homodimer was 
drastically improved by condensation of the 
DNA with additional unmodified polylysine. 
4.3. Intracellular fate and expression of gene 
constructs in various cell types 
Although there is clear evidence regarding the 
first steps of DNA uptake (i.e. receptor binding 
and endocytosis nto internal vesicles), subsequent 
steps by which the DNA is transported to the nu- 
cleus of the cell are still unclear. There is accumu- 
lating evidence that the majority of T f -DNA com- 
plexes are not recycled to the cell surface but are 
delivered into lysosomal and other internal com- 
partments, where they can be still detected more 
than 1 day after transfection [our unpublished re- 
sults]. Nevertheless, in many cell lines, at least 
some of the DNA is transported to the nucleus, 
as expression of marker genes contained on up to 
15-kb large DNA plasmids has been demonstrated 
[150]. LacZ gene transfer into K562 cells (in the 
presence of chloroquine) resulted in a particularly 
high expression of 13-galactosidase b tween day 2 
and day 9 post-transfection, showing that more 
than 90% of the cells expressed the gene. The Tf-  
polylysine method appeared to be particularly 
gentle, with no cytotoxic effects observed. Also 
0.5-1% stable G418-resistant colonies were ob- 
tained upon transfection of K562 cells [150] and 
other cell lines such as the H9 T-cell line [Matt 
Cotten, unpublished results]. A series of TfR-bear- 
ing cells has been successfully transfected with T~ 
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polylysine-DNA complexes, but with significantly 
lower expression levels than in K562 or HD3 ery- 
throid cells; these include [150] human HeLa, 
HepG2, H9, Ewing's sarcoma EW-2 cells, murine 
NIH 3T3 and hamster CHO cells, COS cells, 
chicken EGFR-myb transformed erythroblasts, 
REV-NPB4 lymphoblasts and normal bone mar- 
row cells. The method also has been applied for 
gene transfer to respiratory epithelial cells [151]. 
Calabretta nd colleagues have described the use 
of Tf-polylysine for enhanced elivery of c-myb 
antisense oligonucleotides to HL-60 leukemic 
cells [152]. 
Similar receptor-mediated gene transfer systems 
have been developed using ligands other than 
transferrin: the viral protein HIV gpl20; antibo- 
dies against CD4 or CD7 for the targeting of T- 
cells [150]; asialoglycoprotein [138-143] or syn- 
thetic galactose-containing peptides [153] for the 
targeting of hepatocytes via the asialoglycopro- 
tein receptor; insulin [137, 154]; anti-thrombomo- 
dulin antibody [155-156] for lung targeting, lectins 
such as WGA [157] and additional ligands. 
5. Enhancement of delivery by endosome-disruptive 
viruses or peptides 
5.1. Exit from endosomes as the limiting step of 
delivery 
Although Tf-polycation-DNA complexes pro- 
vide satisfying levels of gene expression in several 
TfR-rich cell lines, in many other cell types the 
expression levels have been very low. Certainly 
there was no clear correlation between TfR levels 
and success of gene transfer; it became apparent 
that it was not receptor binding and uptake into 
endosomes, but later steps in the receptor- 
mediated gene delivery process that were limiting 
factors. In many cell types the reporter gene was 
expressed only in a small fraction (less than 1%) 
of cells, although the DNA had been delivered 
into the vesicular system of most cells. The accu- 
mulation of the complexes in internal vesicles 
seemed to be a major block on the pathway and 
strategies had to be developed to prevent degrada- 
tion of the DNA in lysosomal compartments and 
promote transport to the nucleus. 
In the natural context, after endocytosis many 
non-recycling ligands are targeted to lysosomes 
and degraded by hydrolytic enzymes. A related 
process has been described for gene transfer by 
calcium phosphate precipitation, where over 50% 
of delivered DNA is found degraded in lysosomes 
[158]. A measure to block degradation of material 
in lysosomes involves the use of lysosomotropic 
agents such as chloroquine that might prevent 
acidification of lysosomes and accompanying acti- 
vation of lysosomal hydrolytic enzymes. Including 
chloroquine during the first 4 hours of transfec- 
tion enhances the expression levels in many gene 
transfer experiments mediated by Tf-conjugates 
[146, 147] or other ligand-conjugates [153]. The 
action of chloroquine may be more complex. 
Other lysosomotropic substances that interfere 
with activation of lysosomal enzymes were found 
to be ineffective [150]. Surprisingly, monensin 
which promotes TfR-mediated toxin delivery (see 
Sect. 3.1) antagonizes the action of chloroquine in 
K562 cells. It also appears that incorporation of 
the metabolically stable poly(D)lysine, that might 
be predicted to protect delivered DNA, did not 
influence or improve gene transfer efficiency [149; 
our unpublished observations]. Based on these 
and further findings (see below), it was concluded 
that a major bottleneck of gene transfer is not the 
degradation but the release of DNA complexes 
from endosomes to the cytoplasm. The spectacu- 
lar enhancement of gene transfer by chloroquine 
in K562 cells was then explained by a second me- 
chanism of this agent [159]. In K562 cells the en- 
dosomes reach an unusually low pH due to a de- 
fect in Na + ,K + -ATPase regulation [160]. Presum- 
ably, K562 endosomes accumulate xceptionally 
high amounts of the weak base chloroquine that 
may act osmotically [161], vacuolizing and desta- 
bilizing the endosomes. This also may explain the 
antagonistic effect of monensin, an ionophore that 
prevents the build-up of a pH gradient by a differ- 
ent, non-vacuolizing mechanism. 
5.2. Viral particles promote xit from endosomes 
The Tf-polylysine-DNA complexes share simi- 
larities with natural viruses both in size and in 
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certain entry functions. Similar to viruses, which 
compact heir nucleic acid genome with core pro- 
teins, the DNA is condensed with polylysine. The 
complexes are coated with Tf  as a ligand for at- 
tachment to the cell and for receptor-mediated en-
docytosis, which resembles the entry process of 
viruses such as adenoviruses, influenza virus or 
the picornaviruses. The DNA complexes, how- 
ever, still lack a further important function of vir- 
al entry: the release of the viral genome from en- 
dosomes into the cytoplasm. The normal endoso- 
mal acidification process pecifically activates viral 
coat protein domains that trigger disruption of the 
endosomal membrane, in the case of membrane- 
free viruses such as adenoviruses [77,78], or the 
fusion of the viral membrane with endosomal 
membranes in the case of enveloped viruses such 
as influenza virus [162]. 
In addition, the viral entry functions have been 
found to influence the intracellular delivery of 
other macromolecules [163-165]. Several groups 
observed that the presence of adenoviruses during 
receptor-mediated uptake of macromolecules such 
as Pseudomonas exotoxin conjugates targeted to 
the EGF receptor [77,78] or TfR [49] enhanced 
the entry of the macromolecules into the cell cyto- 
plasm. The question was raised whether the endo- 
some-disruption activity of adenoviruses might be 
used to enhance escape of the larger Tf-polyly- 
s in~DNA particles from vesicular compartments. 
It was found that the replication-defective adeno- 
virus d1312 augmented the levels of Tf-mediated 
gene expression in a dose-dependent manner up 
to more than 2000-fold in many cell lines that ex- 
press high levels of both adenovirus and TfR, such 
as HeLa, KB or CFT1 cells [166]. Because only the 
endosome-disrupting activity of the virus protein 
capsid is thought to be required, it was possible 
to inactivate the viral genome by irradiation with 
short-wave UV or with long-wave UV plus psora- 
len without losing the enhancing activity on DNA 
gene transfer [167]. In contrast to recombinant 
adenoviral vectors, the DNA to be delivered is 
not part of the viral genome which allows flexibil- 
ity in both size and sequence of the delivered 
DNA, demonstrated in examples uch as the func- 
tional delivery of a 48-kb luciferase-encoding cos- 
mid [167]. 
For efficient gene delivery, co-localization of 
both adenovirus and Tf-polylysine-DNA com- 
plexes in the same endosome is essential. Enhance- 
ment of Tf-mediated gene transfer, therefore, is 
only possible if relatively high levels of virus (up 
to more than 10 000 particles/cell) are applied and 
if cells express sufficient levels of adenovirus 
(AdV) receptor. For instance, in K562 cells where 
in the presence of chloroquine Tf-mediated gene 
transfer worked very efficiently (see above) repla- 
cement of chloroquine by free adenovirus particles 
could not generate significant levels of gene ex- 
pression. These drawbacks have been overcome 
by physically linking the adenovirus to the DNA 
complex [159 168169]. For this purpose replica- 
tion-defective adenoviruses were provided with 
DNA-binding polylysine tails, either by direct 
covalent linkage through enzymatic coupling 
[159], by biochemical inkage between biotiny- 
lated viruses and streptavidin-polylysine [168], or 
by immunological linkage through adenoviral cap- 
sid-specific antibody-polylysine conjugates [169]. 
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Fig. 2. Formation (A) and uptake of adenovirus-polylysine/ 
transferrin-polylysine/DNA combination complexes into cells 
(B). 
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Table 2 
TfR-mediated gene delivery 
Cell type Transfection method 
T fpL  TfpL + TfpL + TYpL + T fpL  + 
chloroquine free AdenoV coupled AdenoV Influ pLys 
Hepatocytes 
Hep G2 - +/ -  + + + 
BNL.CI2  - +/ -  +++ + + +++ +++ 
Pr imary - - - + + + + 
Fibroblasts 
3T3 + ++ +++ +++++ ++ 
Mov-13 +/ -  +/ -  + + + + + + 
Mouse L-cells +/ -  + + + + + + + + + 
Pr imary + + + + + 
Myoblast /myotubes 
C2C12 +/ -  +/ -  + + + + + 
G8 +/ -  +/ -  + + + + + 
Pr imary + + + 
Endothelial cells 
Pr imary + / - + + + + + / - 
Human neuroblastoma cell line 
G I -ME-N +/ -  +/ -  + + + + + + + 
HeLa  cells + + + + + + + + + + + + + + + 
Melanoma 
Mouse M-3 + + + + + + + + 
Human pr imary - +/ -  + + + + + + + 
Mouse ES cell 
CCE +/ -  + + + 
Bruce 4 +/ -  + + + + + + 
Erythroid cells 
K562 - + + + + + + + + + + + 
Chicken HD3 + + + + + + + + + + + + + + 
Bone marrow 
Mouse - - + + 
Chicken +/ -  + + + + 
EBV-transformed human B-cells - - - + + + + 
Mouse plasma cell lines (MPCI  1, SP2/0) + + + + + + 
Luciferase activity: +/-  = 1000-10000 light units per l06 cells; + = 10000-1 million light units; + + = 1 5 million light units; 
+ + + = 5 50 million light units; + + + + = 512-100 million light units; + + + + + = > 100 million light units. 
T fpL = transferrin-polylysine; AdenoV = replication-defective adenovirus d1312; Inf lu/pLys = influenza-peptide/polylysine. 
The polycation modification of the virus allows 
ionic binding to the DNA which upon further ad- 
dition of Tf-polylysine is condensed to yield tern- 
ary complexes consisting of both Tf -DNA con- 
densate and adenovirus. Theoretically, these com- 
bination complexes (see Fig. 2) may be interna- 
lized into cells via the TfR and/or the AdV recep- 
tor into the cell. Indeed, ternary complexes have 
been delivered to and expressed at very high levels 
in a broad variety of cell types and a large propor- 
tion of the target cells (80% to almost 100% in cell 
lines such as K562 cells, HepG2 and BNL CL.2 
hepatocyte lines or NIH 3T3 fibroblasts, and 20- 
90% in primary cells such as fibroblasts, hepato- 
cytes, myoblasts, epithelial and endothelial cells, 
or primary melanoma cells). A summary of trans- 
fection efficiencies obtained with the different 
methods of Tf-polylysine mediated gene transfer 
is given in Table 2. It has been shown that block- 
ing of the AdV receptor by antibodies does not 
impair the activity in the gene transfer complex 
[170]. A further important attribute of the ternary 
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DNA condensates resulting from the virus linkage 
has been the finding of effective gene expression 
after transfection with as few as ca. 1 viral parti- 
cle and 100 DNA molecules per cell [159, 168]. 
Also in this respect he system clearly stands out 
against conventional non-viral gene transfer meth- 
ods (see Sect. 4.1) that require the input of several 
hundred thousand DNA molecules. 
Searches for additional viruses that promote 
the release of Tf-DNA complexes from endo- 
somes have led to the identification of alterna- 
tives to the human adenoviruses. As potential can- 
didates, RNA viruses have been considered. De- 
fective Moloney murine leukemia virus particles 
augment gene delivery to a modest extent but are 
limited by the low titers that can be obtained by 
this virus [M.C. and E.W., unpublished ata]. This 
demonstrates that the endosome disruption activ- 
ity is not a unique property of non-enveloped 
viruses, consistent with the cell permeabilization 
studies from Carrasco's group [164]. While 
neither the enveloped influenza virus particles nor 
purified influenza virus hemagglutinin were able 
to augment he gene transfer when incorporated 
in DNA complexes [171; our unpublished results], 
a human rhinovirus augmented the gene transfer 
up to 1000-fold [Dieter Blaas, Ernst Kfichler and 
E.W., unpublished results]. 
A particularly effective alternative to the hu- 
man AdV was found in the CELO virus, a chick- 
en AdV. This virus displays both an endosomoly- 
tic and a gene transfer-enhancing activity similar 
to the human virus [157]. Because the chicken ade- 
novirus is completely defective in mammalian 
cells, no cytopathic effects were observed even at 
high doses of virus that in the case of human E1A- 
defective adenovirus d1312 lead to toxic effects in 
several cell lines such as HeLa cells. The inactivity 
of the chicken virus genome allowed the genera- 
tion of stably transfected cell clones at the high 
frequencies of 1-16% of transfected cells. 
5.3. Enhancement of gene transfer by membrane- 
disruptive peptides 
The gene transfer technique described above 
may become more attractive if virus-free versions 
can be generated in which the virus particles are 
replaced by endosome-disruptive proteins or syn- 
thetic compounds. The study of the membrane 
disruption and fusion processes that occur during 
viral entry and other biologically important mem- 
brane events has led to the identification of am- 
phipathic s-helical peptide sequences that are re- 
sponsible for these membrane processes. The in- 
fluenza virus hemagglutinin structure is particu- 
larly well-studied [162]. The N-terminus of the 
subunit HA-2 contains a membrane-active p p- 
tide sequence which at neutral pH, due to charge 
repulsions between egatively charged amino acid 
side-chain carboxylate groups, is prevented from 
adopting an s-helical conformation. Upon lower- 
ing the pH to 5-6 (i.e. endosomal pH) these 
charges are neutralized by protonation, allowing 
a transition to an s-helical amphipathic structure 
which is able to interact and destabilize lipid mem- 
branes; in the natural context of influenza virus 
structure during entry, this is thought o facilitate 
the fusion of viral and endosomal membrane. 
DNA complexes containing transferrin and 
polylysine have been linked to small synthetic pep- 
tides similar to the N-terminal sequence of hemag- 
glutinin HA-2. In the context of the DNA com- 
plexes, these peptides have been found to disrupt 
membranes in a pH-dependent manner and sub- 
stantially (100- to more than 1000-fold) augment 
Tf-mediated gene transfer in a series of cell lines 
[172, 173]. Upon investigation of several related 
amphipathic peptides it was demonstrated that 
the peptide-containing complexes with highest, 
pH-specific activity in liposome and erythrocyte 
membrane l akage assays also facilitated the most 
efficient gene transfer in cell culture experiments 
[172, 180]. These synthetic gene-transfer vehicles 
(see Fig. 3) on the one hand still have 10- to 100- 
fold lower efficiency than adenovirus-linked DNA 
complexes; on the other hand, they have been 
found to be useful for the generation of stably 
transformed cell lines. Moreover, the synthetic 
gene transfer system represents an interesting 
model for the entry of a natural virus, in that the 
DNA complex contains both Tf  as a ligand for 
endocytosis, and amphipathic peptides as pH-spe- 
cific endosome disrupting agents. 
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Fig. 3. Synthetic virus-like gene transfer system. 
6. Applications and limitations 
6.1. Gene delivery ex vivo and in vivo 
The adenovirus-DNA combination complexes 
can efficiently deliver genes to a large proportion 
(10-90%) of primary cells in culture such as en- 
dothelial cells [174], primary fibroblasts, hepato- 
cytes, myoblasts and primary human melanoma 
cells. However, systemic application of the com- 
plexes by tail vein injection in mice or rats was 
largely unsuccessful due to inactivation of the 
complexes by blood components [E.W., M.C., 
and Kurt Zatloukal, unpublished observations] 
such as the complement system [175,176]. There 
was no significant gene expression in any organ, 
as the majority of complexes were found to be 
accumulated and presumably degraded by the re- 
ticuloendothelial system in liver and spleen. How- 
ever, employing strategies that reduce the interac- 
tion of the complexes with blood (such as local 
injection into the liver of rats) produce significant 
luciferase reporter gene expression of 4 x 106 light 
units/injection site. By clamping off parts of the 
blood supply during the injection, the mixing of 
complexes with the blood was significantly slo- 
wed, and this improved gene transfer about 10- 
fold over the standard injection. In tail veins of 
mice, as a model for in vivo gene transfer to en- 
dothelial cells of blood vessels, a similar gene ex- 
pression was found after local administration with 
the blood supply clamped off for 20 min [Kurt 
Zatloukal, E.W., M.C., and Max Birnstiel, unpub- 
lished results]. Instillation of the complexes into 
the lung has resulted in gene transfer to the air- 
way epithelium [177]--however, at levels that are 
significantly lower that those achieved with recom- 
binant adenovirus vectors. 
6.2. Applications in gene and cancer therapy 
Although receptor-mediated gene transfer in 
vivo shows clear limitations, delivery into primary 
cells in culture is very efficient. The high efficiency 
of delivery to primary cells when the culture envir- 
onment can be controlled will allow the use of this 
system for ex vivo treatment of cells harvested 
from a patient, followed by reimplantation i the 
patient. For example the clotting factor VIII, defi- 
cient in hemophilia A, can be produced by trans- 
fected primary fibroblasts at levels more than 10- 
fold higher than those generated by retroviral vec- 
tors [178]. This will facilitate the generation of 
factor VIII-expressing fibroblast implants for in 
situ expression of this protein. Other applications 
include factor VIII or dystrophin (for the correc- 
tion of muscular dystrophy) expression in myo- 
blasts that will be reimplanted into, and fused 
with, long-lived muscle tissue. 
One exceptionally well-suited application of 
transferrin receptor-mediated gene delivery will 
be in the delivery of genes to tumor cells. Part of 
the success of this approach lies in the rapid pro- 
liferation state and therefore high levels of trans- 
ferrin receptor cycling on tumor cells. One might 
consider using this system to deliver toxin genes 
directly into the tumor mass for elimination of 
these cells. However, the poor survival of our 
complexes in the bloodstream coupled with the 
requirement to introduce the gene into every cell 
in the tumor limits this application. 
Recent advances in the understanding of tumor 
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immunology have promoted the idea of  a tumor 
vaccine. The concept is as follows (Fig. 4): after 
surgical removal of  the tumor  from patients with, 
for example, high-risk pr imary melanoma, a pri- 
mary culture is transfected with one or several 
cytokine genes. X-ray i rradiat ion blocks cell divi- 
sion and the tumor  cells, which continue to live 
and produce cytokine, are appl ied as vaccine that 
is expected to induce a systemic immune response 
against unmodif ied residual tumor cells that other- 
wise lead to metastasis. This gene transfer techni- 
que seems to be part icular ly appl icable for cyto- 
kine gene transfer into tumors because it has sev- 
eral advantages over established protocols,  in that 
a high percentage of  pr imary tumor  cells can be 
targeted, leading to high-level gene expression 
without the need for selecting transfected clones. 
Murine M3 melanoma cells transfected with IL-2 
or I FN-y  gene constructs have been shown to pro- 
duce high levels of  cytokines [179]. In the corre- 
sponding mouse model  the M-3 tumor  cells have 
been injecte d into the flanks of  syngeneic DBA-2 
mice; the control  tumor  cells develop tumors in 6/ 
6 animals within 2 weeks, whereas injection of  M3 
cells transfected with an IL-2 construct have lost 
their tumorigenicity. 
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